Compare ARK Genomic Revolution ETF (ARKG) vs Altria Group Inc (MO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Altria Group Inc — how do they compare? ARK Genomic Revolution ETF trades at $41, while Altria Group Inc trades at $71.99 (market cap $119.88B). The key difference: Altria Group Inc pays a 5.91% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | MO | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $43.57 | $74.55 |
52-Week Low | $23.09 | $54.72 |
Market Cap | — | $119.88B |
Enterprise Value | — | $140.95B |
Dividend Yield | — | 5.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Altria Group (MO) trades at $71.77, up 0.25% on the day, with a bullish technical signal and strong analyst support (16 buy ratings). The stock exhibits robust fundamentals, including a P/E of 14.99, net income margin of 39.52%, and consistent dividend payments, highlighted by a recent $1.06 dividend. Revenue remains stable around $20.1B, though net income dipped to $6.95B in 2025 from $11.3B in 2024. Positive cash flow of $1.33B in 2025 supports financial health, while technical indicators show support at $71 and resistance at $73.
Outlook: MO offers a compelling dividend yield and defensive appeal amid market volatility, but faces risks from declining smoking trends and regulatory pressures. Analyst consensus price target is $71.00, with potential upside to $79.00. Investors should weigh high debt levels and competitive threats against strong cash flow and brand loyalty for long-term income stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
